Advertisement

Pediatric Nephrology

, Volume 29, Issue 12, pp 2289–2298 | Cite as

Calcific uraemic arteriolopathy: a rare disease with a potentially high impact on chronic kidney disease–mineral and bone disorder

  • Vincent M. BrandenburgEmail author
  • Smeeta Sinha
  • Paula Specht
  • Markus Ketteler
Educational Review

Abstract

Calciphylaxis [calcific uraemic arteriolopathy (CUA)] is a rare disease at the interface of nephrology, dermatology and cardiology. CUA most often occurs in adult dialysis patients. It is only rarely seen in patients without relevant chronic kidney disease, and only anecdotal reports about childhood calciphylaxis have been published. Clinically, CUA is characterized by a typical cascade, starting with severe pain in initially often inconspicuous skin areas, followed by progressive cutaneous lesions that may develop into deep tissue ulcerations. The typical picture is a mixture of large retiform ulceration with thick eschar surrounded by violaceous, indurated, tender plaques. The histopathological picture reveals arteriolar, often circumferential, calcification and extensive matrix remodelling of the subcutis. These findings explain the macroscopic correlation between skin induration and ulceration. The prognosis in CUA patients is limited due to underlying comorbidities such as uraemic cardiovascular disease and infectious complications. The etiology of CUA is multifactorial, and imbalances between pro- and anti-calcification factors, especially in the setting of end-stage renal disease play an outstanding role. Oral anticoagulant treatment with vitamin K antagonists is a predominant CUA trigger factor. It is speculative as to why children and adolescents only develop calciphylaxis in exceptional cases, although a seldom usage of vitamin K antagonists and the preserved mineral buffering capacity of the growing skeleton may be protective.

Keywords

Calciphylaxis Calcific uraemic arteriolopathy Chronic kidney disease Calcification Vascular disease 

Notes

Answers to multiple choice questions

(1) a

(2) b

(3) e

(4) d

(5) d

Financial support

The German calciphylaxis registry is supported by a grant from Amgen and Sanofi; the UK Calciphylaxis Study is supported by a grant from Amgen.

References

  1. 1.
    Angelis M, Wong LL, Myers SA, Wong LM (1997) Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery 122:1083–1089PubMedCrossRefGoogle Scholar
  2. 2.
    Selye H (1965) Calciphylaxis. Med Welt 24:1343PubMedGoogle Scholar
  3. 3.
    Selye J (1965) Calciphylaxis and calcergy. Orv Hetil 106:817–821PubMedGoogle Scholar
  4. 4.
    Selye H, Berczi I (1970) The present status of calciphylaxis and calcergy. Clin Orthop Relat Res 69:28–54PubMedCrossRefGoogle Scholar
  5. 5.
    Gipstein RM, Coburn JW, Adams DA, Lee DB, Parsa KP, Sellers A, Suki WN, Massry SG (1976) Calciphylaxis in man. A syndrome of tissue necrosis and vascular calcification in 11 patients with chronic renal failure. Arch Intern Med 136:1273–1280PubMedCrossRefGoogle Scholar
  6. 6.
    Brandenburg V, Al Fakhri N, Nemeth K, Goettsch C, Schurgers LJ, Vermeer C, Hofbauer LC, Schoppet M (2012) Calcification inhibitors in vascular calciphylaxis associated with normal renal function. Thromb Haemost 108:1241–1243PubMedCrossRefGoogle Scholar
  7. 7.
    Weenig RH, Sewell LD, Davis MD, McCarthy JT, Pittelkow MR (2007) Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 56:569–579PubMedCrossRefGoogle Scholar
  8. 8.
    Brandenburg VM, Cozzolino M, Ketteler M (2011) Calciphylaxis: a still unmet challenge. J Nephrol 24:142–148PubMedCrossRefGoogle Scholar
  9. 9.
    Zitt E, Konig M, Vychytil A, Auinger M, Wallner M, Lingenhel G, Schilcher G, Rudnicki M, Salmhofer H, Lhotta K (2013) Use of sodium thiosulphate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients. Nephrol Dial Transplant 28:1232–1240PubMedCrossRefGoogle Scholar
  10. 10.
    Mochel MC, Arakaki RY, Wang G, Kroshinsky D, Hoang MP (2013) Cutaneous calciphylaxis: A retrospective histopathologic evaluation. Am J Dermatopathol 35:582–586PubMedCrossRefGoogle Scholar
  11. 11.
    Kramann R, Brandenburg VM, Schurgers LJ, Ketteler M, Westphal S, Leisten I, Bovi M, Jahnen-Dechent W, Knuchel R, Floege J, Schneider RK (2012) Novel insights into osteogenesis and matrix remodelling associated with calcific uraemic arteriolopathy. Nephrol Dial Transplant 28:856–868PubMedCrossRefGoogle Scholar
  12. 12.
    Nigwekar SU, Bhan I, Turchin A, Skentzos SC, Hajhosseiny R, Steele D, Nazarian RM, Wenger J, Parikh S, Karumanchi A, Thadhani R (2013) Statin use and calcific uremic arteriolopathy: a matched case–control study. Am J Nephrol 37:325–332PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Latus J, Kimmel M, Ott G, Ting E, Alscher MD, Braun N (2011) Early stages of calciphylaxis: are skin biopsies the answer? Case Rep Dermatol 3:201–205PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Shroff R, Long DA, Shanahan C (2013) Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol 24:179–189PubMedCrossRefGoogle Scholar
  15. 15.
    Rogers NM, Coates PT (2008) Calcific uraemic arteriolopathy: an update. Curr Opin Nephrol Hypertens 17:629–634PubMedCrossRefGoogle Scholar
  16. 16.
    Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W (2003) The serum protein alpha 2-Heremans–Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 112:357–366PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Hayashi M, Takamatsu I, Kanno Y, Yoshida T, Abe T, Sato Y (2011) A case–control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant 27:1580–1584PubMedCrossRefGoogle Scholar
  18. 18.
    Fine A, Zacharias J (2002) Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 61:2210–2217PubMedCrossRefGoogle Scholar
  19. 19.
    Mazhar AR, Johnson RJ, Gillen D, Stivelman JC, Ryan MJ, Davis CL, Stehman-Breen CO (2001) Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 60:324–332PubMedCrossRefGoogle Scholar
  20. 20.
    Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS (2012) Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367:2482–2494PubMedCrossRefGoogle Scholar
  21. 21.
    Brandenburg VM, Kramann R, Specht P, Ketteler M (2012) Calciphylaxis in CKD and beyond. Nephrol Dial Transplant 27:1314–1318PubMedCrossRefGoogle Scholar
  22. 22.
    Mawad HW, Sawaya BP, Sarin R, Malluche HH (1999) Calcific uremic arteriolopathy in association with low turnover uremic bone disease. Clin Nephrol 52:160–166PubMedGoogle Scholar
  23. 23.
    Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G (1997) Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386:78–81PubMedCrossRefGoogle Scholar
  24. 24.
    Krueger T, Westenfeld R, Schurgers L, Brandenburg V (2009) Coagulation meets calcification: the vitamin K system. Int J Artif Organs 32:67–74PubMedGoogle Scholar
  25. 25.
    Cozzolino M, Brandenburg V (2010) Warfarin: to use or not to use in chronic kidney disease patients? J Nephrol 23:648–652PubMedGoogle Scholar
  26. 26.
    Kruger T, Brandenburg V, Schlieper G, Marx N, Floege J (2013) Sailing between Scylla and Charybdis: oral long-term anticoagulation in dialysis patients. Nephrol Dial Transplant 28:534–541PubMedCrossRefGoogle Scholar
  27. 27.
    Farah M, Crawford RI, Levin A, Chan YC (2011) Calciphylaxis in the current era: emerging ‘ironic’ features? Nephrol Dial Transplant 26:191–195PubMedCrossRefGoogle Scholar
  28. 28.
    Goodkin DA, Larkina M, Robinson BM (2011) Iron and calciphylaxis. Nephrol Dial Transplant 26:3063–3064PubMedCrossRefGoogle Scholar
  29. 29.
    Hamano T, Matsui I, Mikami S, Tomida K, Fujii N, Imai E, Rakugi H, Isaka Y (2010) Fetuin-mineral complex reflects extraosseous calcification stress in CKD. J Am Soc Nephrol 21:1998–2007PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Herrmann M, Kinkeldey A, Jahnen-Dechent W (2012) Fetuin-A function in systemic mineral metabolism. Trends Cardiovasc Med 22:197–201PubMedCrossRefGoogle Scholar
  31. 31.
    Vedvyas C, Winterfield LS, Vleugels RA (2011) Calciphylaxis: A systematic review of existing and emerging therapies. J Am Acad Dermatol 67:253–260CrossRefGoogle Scholar
  32. 32.
    Brandenburg VM, Schmitz S, Floege J, Amann K, Ketteler M (2011) Calciphylaxis. A call for interdisciplinary cooperation. Hautarzt 62:452–458PubMedCrossRefGoogle Scholar
  33. 33.
    Nigwekar SU, Brunelli SM, Meade D, Wang W, Hymes J, Lacson E Jr (2013) Sodium thiosulfate therapy for calcific uremic arteriolopathy. Clin J Am Soc Nephrol 8:1162–1170PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    O’Neill WC (2013) Sodium thiosulfate: Mythical treatment for a mysterious disease? Clin J Am Soc Nephrol 8:1068–1069PubMedCrossRefGoogle Scholar
  35. 35.
    Torregrosa JV, Duran CE, Barros X, Blasco M, Arias M, Cases A, Campistol JM (2012) Successful treatment of calcific uraemic arteriolopathy with bisphosphonates. Nefrologia 32:329–334PubMedGoogle Scholar
  36. 36.
    Girotto JA, Harmon JW, Ratner LE, Nicol TL, Wong L, Chen H (2001) Parathyroidectomy promotes wound healing and prolongs survival in patients with calciphylaxis from secondary hyperparathyroidism. Surgery 130:645–650PubMedCrossRefGoogle Scholar
  37. 37.
    Bakkaloglu SA, Dursun I, Kaya A, Soylemezoglu O, Hasanoglu E, Buyan N (2007) Digital calciphylaxis progressing to amputation in a child on continuous ambulatory peritoneal dialysis. Ann Trop Paediatr 27:149–152PubMedCrossRefGoogle Scholar
  38. 38.
    Feng J, Gohara M, Lazova R, Antaya RJ (2006) Fatal childhood calciphylaxis in a 10-year-old and literature review. Pediatr Dermatol 23:266–272PubMedCrossRefGoogle Scholar
  39. 39.
    Toprak D, Bircan Z, Gokalp AS (2005) Calciphylaxis due to poor compliance in a child with end stage renal disease: a case report. Pediatr Int 47:95–98PubMedCrossRefGoogle Scholar
  40. 40.
    Amin N, Gonzalez E, Lieber M, Salusky IB, Zaritsky JJ (2010) Successful treatment of calcific uremic arteriolopathy in a pediatric dialysis patient. Pediatr Nephrol 25:357–362PubMedCrossRefGoogle Scholar
  41. 41.
    El Desoky SM, Bockenhauer D, Shroff R, Kari JA (2013) Subcutaneous nodules in a child on long-term dialysis: Questions. Pediatr Nephrol. doi:  10.1007/s00467-013-2571-z
  42. 42.
    Nigwekar SU, Wolf M, Sterns RH, Hix JK (2008) Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol 3:1139–1143PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478–1483PubMedCrossRefGoogle Scholar
  44. 44.
    Shroff R, Degi A, Kerti A, Kis E, Cseprekal O, Tory K, Szabo AJ, Reusz GS (2013) Cardiovascular risk assessment in children with chronic kidney disease. Pediatr Nephrol 28:875–884PubMedCrossRefGoogle Scholar
  45. 45.
    Mitsnefes MM (2012) Cardiovascular disease in children with chronic kidney disease. J Am Soc Nephrol 23:578–585PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Shroff RC, McNair R, Figg N, Skepper JN, Schurgers L, Gupta A, Hiorns M, Donald AE, Deanfield J, Rees L, Shanahan CM (2008) Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 118:1748–1757PubMedCrossRefGoogle Scholar
  47. 47.
    Araya CE, Fennell RS, Neiberger RE, Dharnidharka VR (2006) Sodium thiosulfate treatment for calcific uremic arteriolopathy in children and young adults. Clin J Am Soc Nephrol 1:1161–1166PubMedCrossRefGoogle Scholar
  48. 48.
    Imam AA, Mattoo TK, Kapur G, Bloom DA, Valentini RP (2005) Calciphylaxis in pediatric end-stage renal disease. Pediatr Nephrol 20:1776–1780PubMedCrossRefGoogle Scholar
  49. 49.
    Shroff RC, Shah V, Hiorns MP, Schoppet M, Hofbauer LC, Hawa G, Schurgers LJ, Singhal A, Merryweather I, Brogan P, Shanahan C, Deanfield J, Rees L (2008) The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant 23:3263–3271PubMedCrossRefGoogle Scholar
  50. 50.
    Pasch A, Schaffner T, Huynh-Do U, Frey BM, Frey FJ, Farese S (2008) Sodium thiosulfate prevents vascular calcifications in uremic rats. Kidney Int 74:1444–1453PubMedCrossRefGoogle Scholar
  51. 51.
    Adirekkiat S, Sumethkul V, Ingsathit A, Domrongkitchaiporn S, Phakdeekitcharoen B, Kantachuvesiri S, Kitiyakara C, Klyprayong P, Disthabanchong S (2010) Sodium thiosulfate delays the progression of coronary artery calcification in haemodialysis patients. Nephrol Dial Transplant 25:1923–1929PubMedCrossRefGoogle Scholar

Copyright information

© IPNA 2014

Authors and Affiliations

  • Vincent M. Brandenburg
    • 1
    Email author
  • Smeeta Sinha
    • 2
  • Paula Specht
    • 1
  • Markus Ketteler
    • 3
  1. 1.Department of CardiologyUniversity Hospital RWTH Aachen AachenGermany
  2. 2.Department of Renal Medicine, Manchester Academic Health Sciences CentreSalford Royal NHS Foundation TrustSalfordUK
  3. 3.Department of NephrologyKlinikum CoburgCoburgGermany

Personalised recommendations